Development of Hif1α pharmacogenomic mutation models to study individual variations in drug action for tumor hypoxia: An in silico approach
Objective: Tumor hypoxia, a predominant feature of solid tumor produces drug resistance that significantly impacts a patient's clinical outcomes. Hypoxia-inducible factor 1-alpha (HIF1α) is the major mutation involved in establishing the microenvironment. As a consequence of its involvement in...
Main Authors: | Vaisali Balasubramaniam, P K Krishnan Namboori |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2021-01-01
|
Series: | Journal of Pharmacy and Bioallied Sciences |
Subjects: | |
Online Access: | http://www.jpbsonline.org/article.asp?issn=0975-7406;year=2021;volume=13;issue=4;spage=387;epage=393;aulast=Balasubramaniam |
Similar Items
-
TUMOR HYPOXIA DIAGNOSIS USING DEEP CNN LEARNING STRATEGY A THERANOSTIC PHARMACOGENOMIC APPROACH
by: Vaisali B, et al.
Published: (2019-12-01) -
Vitamin Pharmacogenomics: New Insight into Individual Differences in Diseases and Drug Responses
by: Hai-Yan He, et al.
Published: (2017-04-01) -
Pharmacogenomic profile of actionable molecular variants related to drugs commonly used in anesthesia: WES analysis reveals new mutations
by: Juan Fernando Parada-Márquez, et al.
Published: (2023-03-01) -
Pharmacogenomics Biomarkers of Soft Tissue Sarcoma Therapies
by: Chiara Caruso, et al.
Published: (2020-04-01) -
Pilot Study: Personalized Medicine in Endoscopy, Can Pharmacogenomics Predict Response to Conscious Sedation?
by: Himesh B. Zaver, et al.
Published: (2023-07-01)